A limited supply of cannabis in the U.S. means those resources have to be divvied up carefully. For Cronos Group, that means keeping its medical and recreational marijuana operations in completely different verticals, CEO Michael Gorenstein told Cheddar. That ensures patients’ needs are prioritized over those of recreational users. “If you think about building a town, and you have a limited amount of building supplies, we want to make sure that we’re building a hospital before we’re building the bar,” he said. Canada-based Cronos Group started trading on the NASDAQ on Tuesday, making it the first marijuana company to list on a major U.S. market. “It’s a big milestone not just for us but for the entire industry,” said Gorenstein. “[It] just continues to show the acceptance that the cannabis industry is getting.” And the industry does seem to be growing at break-neck speed. Arcview, a leading researcher of the cannabis market, stated in a [recent report](https://arcviewgroup.com/product/5th-edition/) that the industry brought in $9.7 billion in sales in 2017, and that number could grow to over $25 billion by 2021. For the full interview, [click here](https://cheddar.com/videos/inside-the-first-cannabis-company-to-list-on-nasdaq).

Share:
More In Business
ChatGPT-Related Scams on the Rise
Meta is warning that cybercriminals are tricking people into downloading programs that can steal valuable information on fake ChatGPT offers. Cheddar News explains how Meta has observed hundreds of malicious links on its platform.
Analyst Breaks Down Market as Fed Raises Rates
Will McDonough, founder and CEO of EMG Advisors, joined Cheddar News to discuss Wednesday's trading session after the Federal Reserve raised rates by 0.25% as tighter credit conditions continue to affect small- and medium-sized businesses.
Strategies for Options Traders
Cheddar News' Courtney Sturgeon reports from the Cboe floor with Alan Knuckman, Chief Market Strategist at Bulls Eye Option, to discuss strategies for options traders ahead of a busy trading week amid earnings, the FOMC meeting, and more.
Load More